What’s new in critical illness and injury science? Enhancing anesthetic recovery – Evaluating the role of sugammadex in major abdominal surgeries

The modern approach to anesthetic care increasingly prioritizes precision, safety, and efficiency. A crucial aspect of perioperative management is the reversal of neuromuscular blockade (NMB) at the end of a surgical procedure, a field undergoing significant advancements with the emergence of new pharmacologic agents. The observational study by Ali et al.,[1] titled “Evaluation of efficacy of sugammadex for reversal of neuromuscular blockade in patients undergoing major upper abdominal surgery,” offers strong evidence supporting the growing clinical preference for sugammadex over traditional agents like neostigmine, particularly in complex and high-risk surgical procedures. Neuromuscular blocking drugs (NMBDs) are one of the important components of a balanced anesthesia technique. The aminosteroid nondepolarizing muscle relaxants, particularly rocuronium and vecuronium, are the most widely used in surgical procedures for facilitating tracheal intubation and ensuring optimal operating conditions. However, incomplete or delayed reversal of these agents can result in postoperative residual curarization (PORC), a major risk factor for postoperative pulmonary complications.[2,3] PORC has been linked to adverse outcomes such as hypoxia, aspiration pneumonia, and prolonged hospital stays, highlighting that effective reversal is not merely a pharmacological task but a vital component of patient safety.[4] Historically, neostigmine – a commonly used anticholinesterase – has been the standard agent for reversing NMBDs. However, its indirect mechanism of action, slower onset, and side effect profile (which often necessitates co-administration with antimuscarinic agents such as glycopyrrolate or atropine) can limit its effectiveness, especially in prolonged and complex surgical cases. In contrast, sugammadex, a selective relaxant binding agent, offers a more direct and specific reversal by encapsulating steroidal NMBDs such as rocuronium and vecuronium. This mechanism allows for rapid, reliable, and complete recovery from NMB.[5] The findings from the present study further reinforce the growing clinical confidence in sugammadex as a superior alternative for NMB reversal. Ali et al. conducted a prospective observational study on 50 adult patients undergoing elective major upper abdominal surgeries.[1] The patients were divided into two equal groups: one receiving intravenous (IV) sugammadex and the other receiving IV neostigmine with glycopyrrolate. By using diaphragmatic ultrasonography (DUS) to monitor recovery, the researchers employed a novel and increasingly accepted method of quantifying diaphragm function and assessing PORC.[6,7] Several elements stand out in the study design: Use of DUS: Employing diaphragm thickening fraction (TF) as an objective metric for respiratory muscle function adds granularity and accuracy to the assessment of neuromuscular recovery. This also aligns with the broader shift toward functional markers in perioperative care Standardization of anesthesia and monitoring: All patients underwent similar anesthetic protocols and train-of-four monitoring, minimizing confounding variables Relevant study population: By focusing on major abdominal surgeries – a setting where deeper NMB is often required – the study targets a clinical context where optimized reversal is most crucial. The results of the study are notable and obvious. Patients in the sugammadex group experienced significantly shorter times to extubation (81.96 ± 37.30 s) compared to the neostigmine group (204.20 ± 99.91 s, P < 0.001). More importantly, at 10 min postextubation, the diaphragm thickness and TF were significantly better in the sugammadex group, indicating superior respiratory muscle recovery. Although the incidence of PORC (TF <36%) was not statistically different between the groups (12% vs. 28%, P = 0.157), the numerical trend favors sugammadex, consistent with earlier studies like those by Chen et al.[8] and Hristovska et al.[9] The absence of adverse events in both groups further supports the safety of sugammadex when administered appropriately. The study, although well-conducted, has a few limitations worthnoting. First, the sample size (n = 50) limits the power to detect the differences in relatively rare outcomes such as PORC-related complications. Second, the exclusion of ASA III/IV patients, elderly individuals, and those with comorbidities means that findings may not be generalizable to higher-risk populations. Future studies should expand the demographic scope and consider multicenter designs to improve external validity. In addition, the cost factor of sugammadex remains a debated topic. While sugammadex is significantly more expensive than neostigmine, the potential cost savings from reduced complications, shorter PACU stays, and faster recovery must be weighed against the upfront drug price. Economic evaluations integrated into clinical studies could address this gap. This study contributes meaningful data to the growing body of literature supporting sugammadex as a superior agent for the reversal of NMB in high-risk surgeries. The combination of faster extubation times, improved diaphragm recovery, and the innovative use of DUS for functional assessment makes a strong case for wider adoption of sugammadex, especially in surgeries requiring profound muscle relaxation. Research quality and ethics statement The authors followed applicable EQUATOR Network (https://www.equator-network.org/) guidelines, notably the CARE guideline, during the conduct of this report.